|Description||LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal models of myocardial infarction.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||No Data Available|
|Melting Point||115-117 °C|
CP-105696, a chromen derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied against sorts of nflammatory disease.
ICI-198615 is a novel, potent and selective peptide leukotriene antagonist. It may be useful for the the treatment of allergic diseases.
This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
CP-199330, a chromen derivative, has been found to be a Leukotriene D4 receptor antagonist that was once studied against asthma by Pfizer.
LY-25648 is a leukotriene B4 antagonist.
LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...
This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
LY-306669, a tetrazol derivative, has been found to be a leukotriene B4 receptor antagonist that was once studied its effect in acute lung injury.
Cgp-33304 is a dual phospholipase A2 inhibiting agent and leukotriene receptor antagonists. It may prevent hypoxia secondary to leukotriene induced bronchoconst...
Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of certain natural substances that cau...
Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...
U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.
ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trial...
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
MK-571 sodium salt hydrate
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...